Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

Claims 1-18. (Canceled)

19. (Previously Presented) A compound represented by the general formula (I)




Formula I

wherein:

X is the following radical:




,

L is independently selected from –C(R)(R´´)-, -CO-, and –NR´-;

n is zero, one, two, three, four, five, six, seven, eight, nine or ten;

R and R´´ are independently selected from hydrogen and alkyl;

D is independently selected from –C($R_9$)-, wherein $R_9$ is hydrogen; and –N-;

$A_1$, $A_2$, $A_3$, $A_4$, $A_5$, $A_7$, $A_8$, are independently selected from -C($R_{10}$)($R_{11}$)- and =C($R_{10}$)-;

each of E and G is, independently, -CO- or -$CH_2$-;

$R_1$, $R_2$, $R_3$, and $R_4$, are independently selected from hydrogen and alkoxy; and

$R_{10}$ and $R_{11}$ are independently selected from hydrogen and halo;.

20. (Previously Presented) A compound according to claim 19, wherein X is selected from phthalimide (1,3-dioxo-1,3-dihydro-isoindol-2-yl), 1-indanon-2-yl, and indandion-2-yl.

21. (Previously Presented) A compound according to claim 19, wherein X is phthalimide (1,3-dioxo-1,3-dihydro-isoindol-2-yl) and the cyclic part of formula I represents 9-acridinyl, 1,2,3,4-tetrahydro-acridin-9-yl or 6-chloro, 1,2,3,4-tetrahydro-acridin-9-yl.

22. (Previously Presented) A compound according to claim 19 which is:

- 2-[6-(acridin-9-ylamino)-hexyl]-isoindole-1,3-dione (6),
- 2-[7-(acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (7),
- 2-[8-(acridin-9-ylamino)-octyl]-isoindole-1,3-dione (8),
- 2-[9-(acridin-9-ylamino)-nonyl]-isoindole-1,3-dione (9),

- N-[7-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-heptyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (10),
- N-(3-{[3-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-propyl]-methyl-amino}-propyl)-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (11),
- N-[6-(6-Chloro-1,2,3,4-tetrahydro-acridin-9-ylamino)-hexyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide (12),
- 2-[6-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-hexylamino]-indan-1,3-dione (3),
- 2-[7-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-heptyl]-isoindole-1,3-dione (4), or
- 2-[8-(1,2,3,4-Tetrahydro-acridin-9-ylamino)-octyl]-isoindole-1,3-dione (5).

23. (Previously Presented) A compound according to claim 19, wherein X is 1-indanon-2-yl and the cyclic part of formula I represents 1,2,3,4-tetrahydro-acridin-9-yl.

24. (Previously Presented) A compound according to claim 23, which is:

- 5,6-Dimethoxy-2-{[7-(1,2,3,4-tetrahydro-acridin-9-ylamino)-heptylamino]-methyl}-indan-1-one (1) or
- 5,6-Dimethoxy-2-{[6-(1,2,3,4-tetrahydro-acridin-9-ylamino)-hexylamino]-methyl}-indan-1-one (2).

25. (Previously Presented) A pharmaceutical formulation containing as active ingredient a compound as defined in claim 19.

26. (Withdrawn) A method of treating a cognitive disorder, which comprises administering an effective amount of a compound as defined in claim 19.

27. (Withdrawn) The method of claim 26, wherein the cognitive disorder is senile dementia, cerebrovascular dementia, mild cognition impairment, attention deficit disorder, or a neurodegenerative dementing disease with aberrant protein aggregations.

28. (Withdrawn) The method of claim 27, wherein the neurodegenerative dementing disease with aberrant protein aggregations is Alzheimer´s disease, Parkinson disease, ALS, or prion diseases.

29. (Withdrawn) The method of claim 28, wherein the prion disease is Creutzfeldt-Jakob disease or Gerstmann-Straussler-Scheinher disease.